Results 281 to 290 of about 39,319 (333)

Quantitative Systems Pharmacology Model to Predict Target Occupancy by Bruton Tyrosine Kinase Inhibitors in Patients With B-Cell Malignancies. [PDF]

CPT Pharmacometrics Syst Pharmacol
Demin O, Ou Y, Kolesova G, Shchelokov D, Stepanov A, Musatova V, Sahasranaman S, Zhao Y, Liu X, Tang Z, Hanley WD.   +10 more
europepmc   +1 more source

Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLL. [PDF]

Nat Commun
Arseni L, Sigismondo G, Yazdanparast H, Hermansen JU, Mack N, Ohl S, Kalter V, Iskar M, Kalxdorf M, Friedel D, Rettel M, Paul Y, Ringshausen I, Eldering E, Dubois J, Kater AP, Zapatka M, Roessner PM, Tausch E, Stilgenbauer S, Dietrich S, Savitski MM, Skånland SS, Krijgsveld J, Lichter P, Seiffert M.   +25 more
europepmc   +1 more source

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Journal of Clinical Oncology, 2021
PURPOSE Among Bruton's tyrosine kinase inhibitors, acalabrutinib has greater selectivity than ibrutinib, which we hypothesized would improve continuous therapy tolerability.
Richard R Furman, Neil E Kay, John C Byrd   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Blood, 2023
Key Points • Acalabrutinib has a favorable benefit-risk profile, including lower incidence of cardiovascular-related toxicities, vs ibrutinib.• AE burden score allowed further comparison of the safety of acalabrutinib vs ibrutinib accounting for AE ...
J. Seymour, J. Byrd, P. Ghia, A. Kater, A. Chanan-Khan, R. Furman, S. O'brien, Jennifer R. Brown, T. Munir, A. Mato, S. Stilgenbauer, N. Bajwa, Paulo A Palhares de Miranda, K. Higgins, E. John, M. de Borja, W. Jurczak, J. Woyach   +17 more
semanticscholar   +1 more source

Final analysis of the CLL2-GIVe trial (obinutuzumab, ibrutinib, and venetoclax) in untreated CLL with del(17p)/TP53mut.

Blood, 2023
The final analysis of the open-label, multicenter phase 2 CLL2-GIVe trial shows response and tolerability of the triple combination of obinutuzumab, ibrutinib and venetoclax ("GIVe" regimen) in 41 previously untreated high-risk patients with chronic ...
H. Huber, E. Tausch, C. Schneider, Simone Edenhofer, Julia von Tresckow, S. Robrecht, A. Giza, Can Zhang, M. Fürstenau, P. Dreger, M. Ritgen, T. Illmer, A. Illert, J. Dürig, S. Böttcher, C. Niemann, M. Kneba, O. Al-Sawaf, K. Kreuzer, A. Fink, K. Fischer, H. Döhner, M. Hallek, B. Eichhorst, S. Stilgenbauer   +24 more
semanticscholar   +1 more source

CAR T-cells and Time-Limited Ibrutinib as Treatment for Relapsed/Refractory Mantle Cell Lymphoma: Phase II TARMAC Study.

Blood, 2023
CD19-directed chimeric antigen receptor T-cells achieve high response rates in patients with relapsed or refractory mantle cell lymphoma. However, their use is associated with significant toxicity, relapse is a concern, and their broad tractability is ...
A. Minson, N. Hamad, C. Cheah, Constantine S Tam, P. Blombery, David A. Westerman, David Ritchie, Huw Morgan, N. Holzwart, S. Lade, M. Anderson, A. Khot, J. F. Seymour, M. Robertson, Imogen Caldwell, G. Ryland, J. Saghebi, Zahra Sabahi, Jing Xie, R. Koldej, M. Dickinson   +20 more
semanticscholar   +1 more source

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Journal of Clinical Oncology, 2019
PURPOSE Ibrutinib has shown activity in non-germinal center B-cell diffuse large B-cell lymphoma (DLBCL). This double-blind phase III study evaluated ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in ...
Anas Younes, Peter W M Johnson, Pier Luigi Zinzani   +2 more
exaly   +2 more sources